DOCSLIB.ORG

Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advancing Tuberculosis Vaccines from Discovery to Clinical Development Research Collection Review Article TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development Author(s): Kaufmann, Stefan H.E.; Dockrell, Hazel M.; Drager, Nick; Ho, Mei M.; McShane, Helen; Neyrolles, Olivier; Ottenhoff, Tom H.M.; Patel, Brij; Roordink, Danielle; Spertini, François; Stenger, Steffen; Thole, Jelle; Verreck, Frank A.W.; Williams, Ann; TBVAC2020 Consortium Publication Date: 2017-10-04 Permanent Link: https://doi.org/10.3929/ethz-b-000197748 Originally published in: Frontiers in Immunology 8, http://doi.org/10.3389/fimmu.2017.01203 Rights / License: Creative Commons Attribution 4.0 International This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library REVIEW published: 04 October 2017 doi: 10.3389/fimmu.2017.01203 TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H. E. Kaufmann1*, Hazel M. Dockrell 2, Nick Drager 3, Mei Mei Ho4, Helen McShane5, Olivier Neyrolles 6, Tom H. M. Ottenhoff 7, Brij Patel 8, Danielle Roordink3, François Spertini 9, Steffen Stenger10, Jelle Thole3, Frank A. W. Verreck11, Ann Williams12 and TBVAC2020 Consortium 1 Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 2 Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands, 4 Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom, 5 University of Oxford, Oxford, United Kingdom, 6 Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France, 7 Leiden University Medical Center, Leiden, Netherlands, 8 RegExcel Consulting Ltd, Surrey, United Kingdom, 9 Centre Hospital Universitaire Vaudois, Lausanne, Switzerland, 10 University Hospital of Ulm, Ulm, Germany, Edited by: 11 Biomedical Primate Research Centre, Rijswijk, Netherlands, 12 Public Health England, London, United Kingdom Kuldeep Dhama, Indian Veterinary Research Institute (IVRI), India TBVAC2020 is a research project supported by the Horizon 2020 program of the Reviewed by: European Commission (EC). It aims at the discovery and development of novel tuber- Adel M. Talaat, University of Wisconsin-Madison, culosis (TB) vaccines from preclinical research projects to early clinical assessment. The United States project builds on previous collaborations from 1998 onwards funded through the EC Shoor Vir Singh, framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners Central Institute for Research on Goats (ICAR), India from outstanding laboratories from all over the world, now totaling 40 institutions. Next Ed C. Lavelle, to the development of novel vaccines, TB biomarker development is also considered Trinity College, Dublin, Ireland an important asset to facilitate rational vaccine selection and development. In addition, *Correspondence: TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, Stefan H. E. Kaufmann [email protected] and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between Specialty section: partners with the common aim of working toward the development of an effective TB This article was submitted to Microbial Immunology, vaccine. Close links with funders and other consortia with shared interests further con- a section of the journal tribute to this goal. Frontiers in Immunology Received: 07 July 2017 Keywords: tuberculosis, bacille Calmette–Guérin, vaccination, biomarker, clinical trial, portfolio management, discovery Accepted: 11 September 2017 Published: 04 October 2017 Citation: Kaufmann SHE, Dockrell HM, INTRODUCTION Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, One hundred years ago, Albert Calmette (1863–1933) and Camille Guérin (1872–1961) had almost Roordink D, Spertini F, Stenger S, reached their goal (1). They had passaged Mycobacterium bovis 200 times at 14 d intervals on potato Thole J, Verreck FAW, Williams A slices soaked with ox gall in their attempt to generate an attenuated vaccine against tuberculosis and TBVAC2020 Consortium (2017) (TB). They had started their program in 1906 and had already obtained preliminary evidence for TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to safety and protection of their candidate in 1913. Yet, they continued until they had completed the Clinical Development. 230th passage before verifying its efficacy and safety in experimental animals including guinea pigs, Front. Immunol. 8:1203. rabbits and non-human primates (NHPs) as well as in the natural host, cattle. The data obtained doi: 10.3389/fimmu.2017.01203 were highly promising so Calmette and Guérin started the first vaccination of a human neonate born Frontiers in Immunology | www.frontiersin.org 1 October 2017 | Volume 8 | Article 1203 Kaufmann et al. TBVAC2020 into a household with a TB patient. Risk of TB in a household- research and development and ensured a well-coordinated and contact infant at those times was extremely high. Yet, the baby efficient TB vaccine research consortium. did not develop TB and after additional encouraging results, At the same time, the pipeline needs to be fed constantly with vaccinations of more than 20,000 neonates in households with new innovative candidates since it is unlikely that one single at least one TB patient were performed between 1921 and 1924. vaccine could protect against all different forms of TB disease in The results of this trial revealed that of the vaccinees 5% had died all age groups and for all indications. Thus, the concept of diver- and 1% of these of TB, whereas knowledge of the time held that a sification gained increasing importance. Different vaccine types quarter of non-vaccinated newborns would die in the first years (subunit vaccines vs. whole cell vaccines), different administra- of life, many of them of TB (1). This is the start of Bacille Bilié tion schedules (pre-exposure vs. post-exposure), different age Calmette-Guérin, later shortened to Bacille Calmette–Guérin groups (neonates vs. adults) and different purposes (prevention (BCG), which remains the only licensed vaccine against TB until of infection vs. disease vs. recurrence of disease), and perhaps today. Although not perfect, this vaccine partially fulfills the even therapeutic TB vaccines have all to be considered. goal set by Calmette and Guérin, since it protects against extra- Already before the beginning of TBVAC2020, it was realized pulmonary forms of disease in infants, including life threatening that an isolated vaccine development approach was inadequate TB meningitis. Unfortunately, in most settings, BCG does not and needed to be complemented by deeper knowledge of patho- reliably prevent pulmonary TB, the most prevalent and the most mechanisms, immunology, and microbiology; by established as contagious form in all age groups from the neonatal to the elderly well as novel animal models; by identifying biosignatures of TB population. The lack of an efficient vaccine against pulmonary disease, risk of disease, vaccine efficacy, and safety (3–6). Finally, TB is a major obstacle to control TB satisfactorily until today. with increasing numbers of vaccines being ready for clinical In 1993, the World Health Organization (WHO) declared TB testing, early clinical trials needed to be integrated. Although a global emergency at a time when some 4–6 million new TB TBVAC2020 and its predecessors respect individual researchers’ cases per year were notified. With the introduction of a new treat- autonomy, it was deemed of increasing importance to also pro- ment regimen, called directly observed treatment, short-course vide a portfolio management process, including consensus gating (DOTS) program, WHO claimed to bring TB under control and criteria, to objectively and transparently guide further product predicted a decline from 6–8 million new cases in 1997 to 2–3 and clinical development of TB vaccine candidates (7). This arti- million new cases by 2017 by implementing highly intensive cle describes the different activities of the Horizon 2020 funded DOTS (2). Unfortunately, this hope failed miserably. The most TBVAC2020 project which is coordinated by TBVI summarizing recent notifications reveal a stunning 10.4 million new cases and recent achievements and future goals as part of the European 1.8 million deaths in 2015. Building on better drug regimens effort to successfully combat TB.Figure 1 provides an overview alone not only proved to be insufficient in controlling TB, it also of the close interactions between different WorkPackage (WP) led to increasing incidences of multi-drug-resistant forms of TB. activities and progression of promising vaccine candidates from At this time, researchers interested in the mechanisms under- discovery via preclinical testing to clinical trial. Although TBVI lying immunopathology and immune protection of TB were has coordinated much of the European research efforts on TB concerned that the efficacy of DOTs might be overestimated vaccine development to date, there are other ongoing activities, and considered a better TB vaccine a necessity for efficient TB for example, through the Aeras Foundation1 and the EMI-TB control. Thus, a proposal on TB vaccines was submitted to the Consortium.2 European Commission (EC) funded framework
Load more

Recommended publications
  • Reassessing Twenty Years of Vaccine Development Against Tuberculosis Edited by : Ulrich E
    REASSESSING TWENTY YEARS OF VACCINE DEVELOPMENT AGAINST TUBERCULOSIS EDITED BY : Ulrich E. Schaible and Stefan H. Kaufmann PUBLISHED IN : Frontiers in Immunology Frontiers Copyright Statement About Frontiers © Copyright 2007-2018 Frontiers Media SA. All rights reserved. Frontiers is more than just an open-access publisher of scholarly articles: it is a pioneering All content included on this site, approach to the world of academia, radically improving the way scholarly research such as text, graphics, logos, button icons, images, video/audio clips, is managed. The grand vision of Frontiers is a world where all people have an equal downloads, data compilations and software, is the property of or is opportunity to seek, share and generate knowledge. Frontiers provides immediate and licensed to Frontiers Media SA permanent online open access to all its publications, but this alone is not enough to (“Frontiers”) or its licensees and/or subcontractors. The copyright in the realize our grand goals. text of individual articles is the property of their respective authors, subject to a license granted to Frontiers. Frontiers Journal Series The compilation of articles constituting The Frontiers Journal Series is a multi-tier and interdisciplinary set of open-access, online this e-book, wherever published, as well as the compilation of all other journals, promising a paradigm shift from the current review, selection and dissemination content on this site, is the exclusive property of Frontiers. For the processes in academic publishing. All Frontiers journals are driven by researchers for conditions for downloading and researchers; therefore, they constitute a service to the scholarly community. At the same copying of e-books from Frontiers’ website, please see the Terms for time, the Frontiers Journal Series operates on a revolutionary invention, the tiered publishing Website Use.
    [Show full text]
  • Optimisation, Harmonisation and Standardisation of the Direct
    Journal of Immunological Methods 469 (2019) 1–10 Contents lists available at ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper Optimisation, harmonisation and standardisation of the direct T mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells ⁎ Rachel Tannera, , Steven G. Smithb,1, Krista E. van Meijgaardenc,1, Federico Giannonid, Morven Wilkiea, Lucia Gabrielee, Carla Palmad, Hazel M. Dockrellb, Tom H.M. Ottenhoffc, Helen McShanea a The Jenner Institute, University of Oxford, UK b Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, UK c Department of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands d Department of Infectious Diseases, Istituto Superiore di Sanità, Italy e Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Italy ARTICLE INFO ABSTRACT Keywords: A major challenge to tuberculosis (TB) vaccine development is the lack of a validated immune correlate of Tuberculosis protection. Mycobacterial growth inhibition assays (MGIAs) represent an unbiased measure of the ability to Vaccine control mycobacterial growth in vitro. A successful MGIA could be applied to preclinical and clinical post-vac- Mycobacterial growth inhibition assay cination samples to aid in the selection of novel vaccine candidates at an early stage and provide a relevant MGIA measure of immunogenicity and protection. However, assay harmonisation is critical to ensure that comparable Harmonisation information can be extracted from different vaccine studies. As part of the FP7 European Research Infrastructures for Poverty Related Diseases (EURIPRED) consortium, we aimed to optimise the direct MGIA, assess repeatability and reproducibility, and harmonise the assay across different laboratories.
    [Show full text]
  • Curriculum Vitae
    Biodata: Professor Rabia Hussain ( email: [email protected]) EDUCATION 1966 B.Sc (Hon). Karachi University. Division 1 Position 1 (summa cum laude) Subjects: Microbiology, Biochemistry and Botany. (summa cum laude) 1967 M.Sc. Karachi University, Division 1, Position Subject : Microbiology 1973 PhD, University of Western Ontario Canada, Subject: Immunology Thesis Titles 1968. M.Sc. Thesis: Cross reactions of avian and mammalian gamma globulins, Karachi University, Pakistan 1973. PhD Thesis: Isolation, purification and characterization of an Ascaris suum allergen, University of Western Ontario, Canada. PROFESSIONAL QUALIFICATIONS 1989 : MRC Path: London, U.K. Subject: Immunology 1997 : FRC Path: London, U.K. Subject: Immunology. BRIEF CHRONOLOGY OF EMPLOYMENT 1968-69 Assistant Lecturer, Department of Microbiology, University of Karachi, Karachi, Pakistan 1970-72 Teaching Assistant, Department of Bacteriology and Immunology University of Western Ontario, Canada 1973-75 Research Associate, National Research Council (USA) Naval Medical Research Institute, National Naval Medical Center. 1976-79 Instructor, Department of Medicine, John Hopkins University, USA 1979-81 Collaborative Researcher, National Institutes of Health, National Institutes of Allergy and Infectious Diseases. USA 1981-85 Senior Staff Fellow, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. 1985-90 Associate Professor, Department of Microbiology The Aga Khan University, Karachi, Pakistan Jan - March 2005 2 Acting Chairperson,
    [Show full text]
  • Towards Correlates of Protection for Tuberculosis
    Developments in new TB biomarkers Hazel M Dockrell London School of Hygiene & Tropical Medicine [email protected] - Why do we need biomarkers so badly? - Biomarkers of vaccine immunogenicity - Biomarkers for (early) diagnosis - Correlates of protection - New developments in TB biomarkers - Biomarkers in TBVAC2020 Global pipeline of TB vaccine candidates Foundation to facilitate European efforts Foundation to facilitate European efforts towardstowards the the global global development development of new of new TBTB vaccines vaccines 5www.tbvi.eu March 2008 How can we select better candidates? shifting the risk curve . discovery preclinical Phase I Phase II Phase III RISK prediction of likely efficacy in preclinical plus early human trials assessment of efficacy in Phase IIB clinical trial MONEY Biomarkers of immunogenicity following vaccination Immunogenicity of BCG in UK infants: IFNg UNVAC BCG VAC 1 1 n=51 n=36 .8 .8 .6 .6 proportion .4 proportion .4 .2 .2 0 0 0 31 62 125 250 500 1000 2000 4000 8000 0 31 62 125 250 500 1000 2000 4000 8000 IFN-g response (pg/ml) IFN-g response (pg/ml) • 3 months after BCG vaccination at 3-13 weeks of age, 100% of the UK infants given BCG vaccination made IFNg responses >62pg/ml to PPD; none of the unvaccinated infants were IFNg responders (Lalor et al JID 2009, 199:795) TBVAC-associated sub-unit TB vaccines: MVA85A Phase 1 –trial in Immunogenicity: PPD neg excellent primary response MVA85A alone or Safety: low reactogenicity BCG + MVA85A 750 IFNg-ELISPOT 500 PBMC 6 MVA85A BCG + MVA85A 250 SFC/1x10
    [Show full text]
  • Factors Influencing the Higher Incidence of Tuberculosis Among Migrants and Ethnic Minorities in the UK [Version 2; Peer Review: 2 Approved]
    F1000Research 2018, 7:461 Last updated: 21 AUG 2021 REVIEW Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK [version 2; peer review: 2 approved] Sally Hayward 1, Rosalind M. Harding2, Helen McShane3, Rachel Tanner 3 1St John’s College, University of Oxford, Oxford, OX1 3JP, UK 2Department of Zoology, University of Oxford, Oxford, OX2 6GG, UK 3The Jenner Institute, University of Oxford, Oxford, OX1 3PS, UK v2 First published: 13 Apr 2018, 7:461 Open Peer Review https://doi.org/10.12688/f1000research.14476.1 Latest published: 20 Aug 2018, 7:461 https://doi.org/10.12688/f1000research.14476.2 Reviewer Status Invited Reviewers Abstract Migrants and ethnic minorities in the UK have higher rates of 1 2 tuberculosis (TB) compared with the general population. Historically, much of the disparity in incidence between UK-born and migrant version 2 populations has been attributed to differential pathogen exposure, (revision) report due to migration from high-incidence regions and the transnational 20 Aug 2018 connections maintained with TB endemic countries of birth or ethnic origin. However, focusing solely on exposure fails to address the version 1 relatively high rates of progression to active disease observed in some 13 Apr 2018 report report populations of latently infected individuals. A range of factors that disproportionately affect migrants and ethnic minorities, including genetic susceptibility, vitamin D deficiency and co-morbidities such as 1. Jessica L. Potter , Queen Mary University diabetes mellitus and HIV, also increase vulnerability to infection with of London, London, UK Mycobacterium tuberculosis (M.tb) or reactivation of latent infection.
    [Show full text]
  • Replacing, Reducing and Refining the Use of Animals in Tuberculosis
    Review Article Replacing, Reducing and Refining the Use of Animals in Tuberculosis Vaccine Research Rachel Tanner and Helen McShane The Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK Summary Tuberculosis (TB) remains a serious global health threat and an improved vaccine is urgently needed. New candidate TB vaccines are tested using preclinical animal models such as mice, guinea pigs, cattle and non-human primates. Animals are routinely infected with virulent Mycobacterium tuberculosis (Mtb) in challenge experiments to evaluate protective efficacy, raising ethical issues regarding the procedure of infection itself, symptoms of disease and humane end-points. We summarize the importance and limitations of animal models in TB vaccine research and review current alternatives and modifications in the context of the NC3Rs framework for replacing, reducing and refining the use of animals for scientific purposes. Keywords: tuberculosis, vaccine, animal models, Mtb challenge, 3Rs 1 Introduction human-like pulmonary and extrapulmonary lesions observed (Basaraba, 2008; McMurray et al., 1996). Despite the utility of Tuberculosis (TB) is the world’s most deadly infectious disease, small animals in early screens, larger animal models such as with an estimated 9.6 million new cases and 1.5 million deaths cattle and NHPs are considered more relevant to human TB. annually (WHO, 2016). Incidence of infection in endemic coun- NHPs are naturally susceptible to infection with Mtb, and de- tries remains very high despite good coverage with BCG (Ba- velop the most human-like disease with latency and reactivation cillus Calmette-Guérin) vaccine, the only currently available (Flynn et al., 2015). BCG confers some level of protection in vaccine (Mahomed et al., 2006; Moyo et al., 2010).
    [Show full text]
  • TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
    REVIEW published: 04 October 2017 doi: 10.3389/fimmu.2017.01203 TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H. E. Kaufmann1*, Hazel M. Dockrell 2, Nick Drager 3, Mei Mei Ho4, Helen McShane5, Olivier Neyrolles 6, Tom H. M. Ottenhoff 7, Brij Patel 8, Danielle Roordink3, François Spertini 9, Steffen Stenger10, Jelle Thole3, Frank A. W. Verreck11, Ann Williams12 and TBVAC2020 Consortium 1 Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 2 Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands, 4 Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom, 5 University of Oxford, Oxford, United Kingdom, 6 Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France, 7 Leiden University Medical Center, Leiden, Netherlands, 8 RegExcel Consulting Ltd, Surrey, United Kingdom, 9 Centre Hospital Universitaire Vaudois, Lausanne, Switzerland, 10 University Hospital of Ulm, Ulm, Germany, Edited by: 11 Biomedical Primate Research Centre, Rijswijk, Netherlands, 12 Public Health England, London, United Kingdom Kuldeep Dhama, Indian Veterinary Research Institute (IVRI), India TBVAC2020 is a research project supported by the Horizon 2020 program of the Reviewed by: European Commission (EC). It aims at the discovery and development of novel tuber- Adel M. Talaat, University of Wisconsin-Madison, culosis (TB) vaccines from preclinical research projects to early clinical assessment. The United States project builds on previous collaborations from 1998 onwards funded through the EC Shoor Vir Singh, framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners Central Institute for Research on Goats (ICAR), India from outstanding laboratories from all over the world, now totaling 40 institutions.
    [Show full text]
  • Secreting CD8 T Lymphocytes Specific for Mycobacterium
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 270–275, January 1998 Immunology Human cytolytic and interferon g-secreting CD81 T lymphocytes specific for Mycobacterium tuberculosis i AJIT LALVANI*†,ROGER BROOKES*†‡,ROBERT J. WILKINSON§¶,ADAM S. MALIN ,ANSAR A. PATHAN*, i PETER ANDERSEN**, HAZEL DOCKRELL ,GEOFFREY PASVOL¶, AND ADRIAN V. S. HILL* *Molecular Immunology Group, Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; §Tuberculosis and Related Infections Unit, Royal Postgraduate Medical School, London W12 0NN, United Kingdom; ¶Department of Infection and Tropical Medicine, Imperial College School of Medicine, Northwick Park Hospital, London HA1 3UJ, United Kingdom; iClinical Sciences, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E, United Kingdom; and **Tuberculosis Unit, Staatens Seruminstitut, Artileriweg 5, Copenhagen-S, Denmark DK2300 Edited by Barry R. Bloom, Albert Einstein College of Medicine, Hasting-on-Hudson, NY, and approved October 28, 1997 (received for review July 11, 1997) ABSTRACT Protective immunity to Mycobacterium tuber- Two secreted antigens of M. tuberculosis, early secretory culosis is poorly understood, but mounting evidence, at least in antigenic target 6 (ESAT-6) and the Antigen 85 complex, were animal models, implicates major histocompatibility complex studied because secreted antigens are implicated as targets of class I-restricted CD81 T cells as an essential component. By protective immune responses (8) and are more likely to access using a highly sensitive assay for single cell interferon g the host cell cytosol and hence the MHC class I antigen release, we screened an array of M. tuberculosis antigen- processing pathway.
    [Show full text]
  • Kaufmann, Stefan H. E. and Dockrell, Hazel M. and Drager, Nick and Ho, Mei Mei and Mcshane, Helen and Neyrolles, Olivier and Ottenhoff, Tom H
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Strathclyde Institutional Repository Kaufmann, Stefan H. E. and Dockrell, Hazel M. and Drager, Nick and Ho, Mei Mei and McShane, Helen and Neyrolles, Olivier and Ottenhoff, Tom H. M. and Patel, Brij and Roordink, Danielle and Spertini, François and Stenger, Steffen and Thole, Jelle and Verreck, Frank A. W. and Williams, Ann and Britton, Warwick and Triccas, Jamie and Counoupas, Claudio and Grooten, Johan and Marie-Ange Demoitie, Demoitie and Romano, Marta and Huygen, Kris and Tima, Hermann Giresse and Mascart, Francoise and Andersen, Peter and Aagaard, Claus and Christensen, Dennis and Ruhwald, Morten and Lindenstrom, Thomas and Charneau, Pierre and Guilhot, Christophe and Peixoto, Antonio and Gilleron, Martine and Vergne, Isabelle and Locht, Camille and Brosch, Roland and Inchauspe, Genevieve and Theung Long, Stephane Leung and Weiner, January and Maertzdorf, Jeroen and Nieuwenhuizen, Natalie and Bastian, Max and Kallert, Stephanie and Gordon, Stephen and Caccamo, Nadia and Goletti, Delia and Nisini, Roberto and Shin, Sung Jae and Cho, Sang Nae and Lee, Hyejon and Choi, Ino and Sigal, Alex and Scriba, Thomas and Walzl, Gerhard and Loxton, Andre and Wilkinson, Robert and Wilkinson, Katalin and Cardona, Pere Joan and Vilaplana, Cris and Martin, Carlos and Marinova, Dessi and Aguilo, Nacho and Aebersold, Ruedi and Caron, Etienne and Pinschewer, Daniel and De Libero, Gennaro and Siegrist, Claire Anne and Collin, Nicolas and Barnier-Quer,
    [Show full text]
  • Richardus, JH; Ideal Consortium, (2005)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by LSHTM Research Online Aseffa, A; Brennan, P; Dockrell, H; Gillis, T; Hussain, R; Oskam, L; Richardus, JH; Ideal Consortium, (2005) Report on the First Meeting of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) Consortium held at Armauer Hansen Research Institute, ALERT, Addis Ababa, Ethiopia on 24-27 October 2004. Leprosy re- view, 76 (2). pp. 147-59. ISSN 0305-7518 Downloaded from: http://researchonline.lshtm.ac.uk/12081/ DOI: Usage Guidelines Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna- tively contact [email protected]. Available under license: Copyright the publishers Lepr Rev (2005) 76, 147–159 SPECIAL PAPER Report on the First Meeting of the IDEAL (Initia- tive for Diagnostic and Epidemiological Assays for Leprosy) Consortium held at Armauer Hansen Research Institute, ALERT, Addis Ababa, Ethiopia on 24–27 October 2004 ABRAHAM ASEFFA, PATRICK BRENNAN, HAZEL DOCKRELL, TOM GILLIS, RABIA HUSSAIN, LINDA OSKAM & JAN HENDRIK RICHARDUS ON BEHALF OF THE IDEAL CONSORTIUM Accepted for publication 18 February 2005 Introduction The IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) consortium was established following a WHO/TDR sponsored workshop held in Amsterdam in October 2003, in which strategies for the development of new diagnostic and epidemiological assays, based on these technical developments, were defined. An Interim Steering Committee was appointed with the objective to set up a network of relevant research and field sites, write a coordinated research proposal and, where possible, coordinate activities between partners.
    [Show full text]
  • Differences Between Naive and Memory T Cell Phenotype In
    BMC Infectious Diseases BioMed Central Research article Open Access Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus? Anne Ben-Smith†1, Patricia Gorak-Stolinska*†1, Sian Floyd1, Rosemary E Weir1, Maeve K Lalor1, Hazzie Mvula2, Amelia C Crampin2, Diana Wallace3, Peter CL Beverley4, Paul EM Fine1 and Hazel M Dockrell1 Address: 1Department of Infectious and Tropical Diseases, Keppel Street, London, WC1E 7HT, UK, 2Karonga Prevention Study, Chilumba, Malawi, 3Department of Immunology and Molecular Pathology, UCL, London, WIT 4JF, UK and 4The Jenner Institute, Compton, Newbury, Berkshire, RG20 7NN, UK Email: Anne Ben-Smith - [email protected]; Patricia Gorak-Stolinska* - [email protected]; Sian Floyd - [email protected]; Rosemary E Weir - [email protected]; Maeve K Lalor - [email protected]; Hazzie Mvula - [email protected]; Amelia C Crampin - [email protected]; Diana Wallace - [email protected]; Peter CL Beverley - [email protected]; Paul EM Fine - [email protected]; Hazel M Dockrell - [email protected] * Corresponding author †Equal contributors Published: 15 October 2008 Received: 31 March 2008 Accepted: 15 October 2008 BMC Infectious Diseases 2008, 8:139 doi:10.1186/1471-2334-8-139 This article is available from: http://www.biomedcentral.com/1471-2334/8/139 © 2008 Ben-Smith et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Immunology Host-Pathogen Interaction in Tuberculosis We Study
    Immunology Host-pathogen interaction in tuberculosis LSHTM investigators: Ulrich Schaible, Daniel Korbel (Postdoc) Collaborators: Albert Haas, Konrad Sandhoff, University of Bonn, Germany; Stefan H.E. Kaufmann, MPI Infection Biology, Berlin, Germany; Germaine Puzo, University of Toulouse, France; Robert Simpson; Andy McKie; Robert Hider, Kings College, London; Gurdiyal Besra, University of Birmingham; Ingrid Mueller, Imperial College, London; Hartmut Oschkinat, FMP, Berlin; Gareth Griffiths, EMBL, Heidelberg; Jorge Escalante-Semerena, University of Wisconsin, Madison, USA; James Shayman, University of Michigan, Ann Arbor, USA Funding bodies: Royal Society, German Science Foundation, MRC Capacity Building Area Studentship, funding applied from Wellcome Trust We study various aspects of host-pathogen interactions in tuberculosis and other infec- tions with intracellular pathogens. Tuberculosis is the most important bacterial infection worldwide in humans caused by Mycobacterium tuberculosis. Main research topics are the pathways for presentation of mycobacterial antigens (including lipids), T cell activa- tion and recruitment at the site of infection and interaction between cells of the innate and acquired immune system, role of nutrients such as iron for disease development and bacterial growth, and survival mechanisms of mycobacteria. We bring together molecular immunology and cellular microbiology through experimental approaches on molecular, cellular as well as the experimental animal model levels to answer these questions. We hypothesize that the intracellular niche of mycobacteria is of pivotal importance to under- stand mycobacterial virulence and immunity in tuberculosis. Blocking phagosome maturation by mycobacteria allows access to iron essential for mycobacterial growth, and secludes the bacteria from hostile lysosomes and antigen pro- cessing pathways. We identified proteins and lipids which are upregulated during intra- cellular growth of mycobacteria.
    [Show full text]